Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itraconazole plus nebulized Ambisome versus itraconazole alone for chronic pulmonary aspergillosis
2018-000972-14Phase 3Active
- Sponsor
- CHU de Poitiers
- Start
- Mar 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in chronic pulmonary aspergillosis (CPA) comparing Itraconazole plus nebulized Ambisome with Itraconazole alone (2 arms). Primary endpoint: Therapeutic efficacy at 6 months. Started Mar 2018; status: active.
02
Drugs
itraconazoleamphotericin b
03
Conditions
chronic pulmonary aspergillosis (CPA)
Beyond the preview
Go deeper on 2018-000972-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000972-14.